RT aHUSAllianceAct RT KioaWijnsma: Net samen met Nicolevandekar Capita Selecta radboudumc verzorgt voor #medicalstudents belangrijk onderwerp voor toekomstige dokters https://t.co/zTGPWNhNxn
RT @KioaWijnsma: Net samen met @Nicolevandekar Capita Selecta @radboudumc verzorgt voor #medicalstudents belangrijk onderwerp voor toekomst…
RT @KioaWijnsma: Net samen met @Nicolevandekar Capita Selecta @radboudumc verzorgt voor #medicalstudents belangrijk onderwerp voor toekomst…
Net samen met @Nicolevandekar Capita Selecta @radboudumc verzorgt voor #medicalstudents belangrijk onderwerp voor toekomstige dokters https://t.co/NvlNTvjeNh
RT aHUSAllianceAct Is there a limit to how much a life-saving drug should cost annually per #patient? Government policies & regs for #orphandrugs vary by nation, and may withhold #drugs solely due to high price & cost-effectiveness. #raredisease #
Is there a limit to how much a life-saving drug should cost annually per #patient? Government policies & regs for #orphandrugs vary by nation, and may withhold #drugs solely due to high price & cost-effectiveness. #raredisease #pharma #eculizumab
RT @aHUSAmerica: Forgetfulness re #medication compliance? Or other reasons why #patients don’t take their medications, such as #drug costs,…
Forgetfulness re #medication compliance? Or other reasons why #patients don’t take their medications, such as #drug costs, possibility of side effects, or desire to be less reliant on drugs @nytimes https://t.co/S3RpkZ381A Re #OrphanDrugs cost https://t.co
RT aHUSAllianceAct Access to Treatment: aHUSAllianceAct #whitepaper re #aHUS #RareDisease #OrphanDrug https://t.co/GQevsLKFhn … Global atypical HUS #PatientExperience #SHUa Orphan drug policies & use in pediatric #nephrology: https://t.co/f7qNWLMPOp #p
Access to Treatment: @aHUSAllianceAct #whitepaper re #aHUS #RareDisease #OrphanDrug https://t.co/OBpqGmeFiR … Global atypical HUS #PatientExperience #SHUa Orphan drug policies & use in pediatric #nephrology: https://t.co/1xtBZZIHMA #pharma #pharmacoeco
RT aHUSAllianceAct #Drug pricing & #reimbursement vary by country and impact #raredisease patient #healthcare. https://t.co/f7qNWLMPOp #ec…
#Drug pricing & #reimbursement vary by country and impact #raredisease patient #healthcare. https://t.co/1xtC000iE8 #eculizumab #nephrology
RT @aHUSAmerica: #pharmacoeconomics Orphan drug policies and use in pediatric nephrology. #raredisease #research #whywedoresearch https:…
RT @aHUSAmerica: #pharmacoeconomics Orphan drug policies and use in pediatric nephrology. #raredisease #research #whywedoresearch https:…
RT @aHUSAmerica: #pharmacoeconomics Orphan drug policies and use in pediatric nephrology. #raredisease #research #whywedoresearch https:…
#pharmacoeconomics Orphan drug policies and use in pediatric nephrology. #raredisease #research #whywedoresearch https://t.co/QVAX1ti5Bu https://t.co/SZVpE2NEqq
#Orphandrug policies & use in pediatric #nephrology https://t.co/Z5bVTvgaNZ #pharmacoeconomics affect #patient treatment access #aHUS #SHUa https://t.co/wybmN6FolJ
RT @jbcarmody: @ISNkidneycare @kidgenaustralia @amandanewnham Great review recently on policy/ethical issues with #orphandrugs in pediatric…
#Orphandrug policies & use in pediatric #nephrology https://t.co/wsN6O6gVYF #Pharmacoecomics #RareDisease #aHUS #SHUa @aHUSAllianceAct https://t.co/IWTQZpYfIY
RT @jbcarmody: @ISNkidneycare @kidgenaustralia @amandanewnham Great review recently on policy/ethical issues with #orphandrugs in pediatric…
RT @jbcarmody: @ISNkidneycare @kidgenaustralia @amandanewnham Great review recently on policy/ethical issues with #orphandrugs in pediatric…
@ISNkidneycare @kidgenaustralia @amandanewnham Great review recently on policy/ethical issues with #orphandrugs in pediatric #nephrology, from @Ped_Neph https://t.co/PLaDBcd0DI
RT @IPNA_PedNeph: Interesting discussion: how much should a life-saving drug cost annually per patient? #springerlink https://t.co/pTFauvo…
Access to & cost of #nephrology #orphandrugs; ethical impact far beyond #peds #aHUS #Fabry #cystinosis #patients https://t.co/C3GluoxmfI https://t.co/sY7zD9puth
#Orphandrugs Policy & Regs-Restrict #aHUS drug #eculizumab due to high price & cost-effectiveness?Same for #Fabry & #cystinosis? #nephrology https://t.co/b4mk6jpfYD
RT @IPNA_PedNeph: Interesting discussion: how much should a life-saving drug cost annually per patient? #springerlink https://t.co/pTFauvo…
More access to #orphandrugs needed: role of CO$T #raredisease #research & #policy re #pediatric #nephrology https://t.co/pqIOhttB52 #pharma
RT @IPNA_PedNeph: Interesting discussion: how much should a life-saving drug cost annually per patient? #springerlink https://t.co/pTFauvo…
Pricing of 3 drugs in paediatric nephrology: eculizumab (#aHUS), agalsidase b (Fabry) and cysteamine (cystinosis). https://t.co/fkd0TAKAyY
RT @IPNA_PedNeph: Interesting discussion: how much should a life-saving drug cost annually per patient? #springerlink https://t.co/pTFauvo…
RT @aHUSUKvoice: Wanted ethics equity and economy in rare disease patients orphan drugs solution https://t.co/JYftarB1sg
RT @IPNA_PedNeph: Interesting discussion: how much should a life-saving drug cost annually per patient? #springerlink https://t.co/pTFauvo…
RT @IPNA_PedNeph: Interesting discussion: how much should a life-saving drug cost annually per patient? #springerlink https://t.co/pTFauvo…
RT @aHUSUKvoice: Wanted ethics equity and economy in rare disease patients orphan drugs solution https://t.co/JYftarB1sg
RT @aHUSAllianceAct: Access and CO$T of #orphandrugs have profound financial & #ethical implications for #patients, #hospitals, #healthcare…
Interesting discussion: how much should a life-saving drug cost annually per patient? #springerlink https://t.co/pTFauvoE8V
RT @aHUSUKvoice: Wanted ethics equity and economy in rare disease patients orphan drugs solution https://t.co/JYftarB1sg
RT @aHUSAllianceAct: Access and CO$T of #orphandrugs have profound financial & #ethical implications for #patients, #hospitals, #healthcare…
Getting the ethics/equity/economics mix right for #raredisease patients @aHUSAllianceAct @rarediseaseuk @RarediseasesSA https://t.co/2plpjOHKu9
Wanted ethics equity and economy in rare disease patients orphan drugs solution https://t.co/JYftarB1sg
Access and CO$T of #orphandrugs have profound financial & #ethical implications for #patients, #hospitals, #healthcare policy #RareDisease https://t.co/4grtFvH3Wh
National advisory committees and pharmaceutical companies should work together and saving lives!! https://t.co/eQOw9LqzSl
RT @rheault_m: "Is there a limit to how much a life-saving drug should cost annually"? Perspectives from Ped Neph rare disease https://t.c…
RT @rheault_m: "Is there a limit to how much a life-saving drug should cost annually"? Perspectives from Ped Neph rare disease https://t.c…
RT @Ped_Neph: NEW #openaccess editorial: Orphan drug policies and use in pediatric nephrology - @lunduniversity #springerlink https://t.co/…
RT @ASPNeph: Orphan drug policies and use in pediatric nephrology https://t.co/SQOU8yMNHx @Ped_Neph
RT @ASPNeph: Orphan drug policies and use in pediatric nephrology https://t.co/SQOU8yMNHx @Ped_Neph
And that also benchmarked over other non nephrology diseases..! https://t.co/vjrgqanhKm
"Is there a limit to how much a life-saving drug should cost annually"? Perspectives from Ped Neph rare disease https://t.co/8Z8J33fopX
NEW #openaccess editorial: Orphan drug policies and use in pediatric nephrology - @lunduniversity #springerlink https://t.co/qLWH8qftsQ
Orphan drug policies and use in pediatric nephrology https://t.co/SQOU8yMNHx @Ped_Neph